Apoptosis Assay Market Size Worth $7.5 Billion By 2027

The global apoptosis assay market size is expected to reach USD 7.5 billion by 2027, expanding at a CAGR of 7.6%, according to a new report by Grand View Research, Inc. Extensive research activities on expanding applications of drug-induced apoptosis assays have propelled the inclination of pharmaceutical manufacturers towards incorporating cell cycle products in the drug discovery and designing process.

The introduction of affordable and easy to perform kits that can be accommodated in complex experiments is expected to minimize the overhead costs of apoptosis experiments. Companies are providing highly precise reagents and lot-to-lot reproducibility in sample measurements.

Professionals at pharmaceutical companies are making use of cell-cycle inhibitors and Apoptosis-Inducing Factors (AIF)/ molecules to explore possible drug targets. Also, high demand for caspase activity assays along with Bcl-2 protein family across pharmaceutical companies for apoptosis detection has been observed in recent years. Biotechnology companies are enhancing quantification techniques to enable real-time monitoring of apoptotic cellular dynamics.

The presence of established guidelines and protocols for cell-potency assays has strengthened the development of efficient cell-death detection assays. Whereas, stringent regulations with respect to the approval of cell-potency assays are ensuring successful uptake of market products launched.

The flow cytometry segment dominated the market and accounted for the largest revenue share in 2019. This is attributed to the increasing adoption of the technique among researchers. It helps in finding the difference between intact mitochondria (healthy cells) and permeabilized mitochondria (cells undergoing death). The segment is anticipated to grow fast over the forecast period.

The pharmaceutical and biotechnology segment dominated the market in 2019 and is anticipated to continue its dominance over the forecast period. This is attributed to the rising incidence of cancer and neurodegenerative disorders. In addition, the growing significance of programmed cell death or apoptosis to treat chronic diseases is driving the segment growth.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/apoptosis-market

Further key findings from the study suggest:

The kits segment dominated the market and accounted for a revenue share of around 50.0% owing to increasing investment by key market players
Increase in the demand for fluorochrome-labeled inhibitors of caspases has made reagents the fastest growing product segment in the market
Application of these inhibitors with other techniques is anticipated to enhance the apoptosis assessment, thereby driving segment growth
Owing to the wide adoption and easy availability of products, flow cytometry is estimated to account for a substantial share of approximately 35.0% in 2019
The increasing significance of continuous monitoring of programmed cell death across novel drug discoveries and development of advanced therapeutics is set to propel market growth
North America has dominated the market in terms of revenue share in 2019, and Asia Pacific is expected to witness the fastest growth in the coming years as a result of the expanding CRO landscape in the region
Key companies are competing in terms of a combination of products and services in order to maintain market share.

Protein Labeling Market Size Worth $2.60 Billion By 2024

The global protein labeling market size is expected to reach USD 2.60 billion by 2024, according to a new report by Grand View Research, Inc., registering a CAGR of 9.3% during the forecast period. Development and commercial launch of high accuracy and rapid labeling products is expected to enhance market growth.

Post-translation Modification (PTM) such as proteolysis, lipidation, acetylation, methylation, nitrosylation, ubiquitination, glycosylation, and phosphorylation influence all aspects of pathogenesis as well as normal cell functioning. PTM studies are rapidly being adopted to investigate biological functions of various proteins and their role in disease prognosis.

Availability of a broad range of labels for covalent attachment of different molecules provides researchers the choice to select labels to suit specific applications. Fluorescent labeling does not require additional reagents for protein detection due to its ability to respond to light signals. This ability of fluorescence molecules has significantly contributed to its rapid adoption in in vivo protein labeling.

High R&D spending to reduce complexity in protein labeling and increased adoption of sophisticated bioengineering techniques in various sectors of biotechnology further contribute to market growth. Development of rapid diagnostic tests based on detection of the presence of specific protein proves to be of great significance for rapid and cost-effective diagnostics. Focus on development of advanced diagnostic tests based on protein detection is expected to fuel new product development.

Technological advancements in genetic sequencing methodologies has drastically reduced the cost of genome profiling. This is expected to drive demand for protein expression analysis, which is the next step in genetic analysis after sequencing. Declining sequencing cost has increased the number of proteomic and genomic profiling studies, which is projected to fuel demand for protein labeling over the forecast period.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/protein-labeling-market

Further key findings from the report suggest:

Rapid adoption of post-translational modification studies in proteomics is expected to fuel demand for reagents
SNAP-, CLIP-, MCP-, and ACP- tags are some of the fusion proteins used for covalent labeling. Ability to provide irreversible covalent labeling and labeling for membrane protein drives demand for probes/tags in labeling
Demand for kits for clinical diagnosis of various diseases based on protein detection fuels the kits product segment
North America dominated the market due to presence of key players and high investments in proteomics research. Canada is poised to witness lucrative growth owing to increasing number of research projects focused on improving healthcare solutions
Europe is a key regional market. The Seventh Framework Program of the European Union provided funds for P-CUBE – an infrastructure for Protein Production Platforms to provide access to most advanced techniques to researchers
Asia Pacific is expected to observe remarkable growth over the forecast period, especially in China and Japan
Major companies operating in the market include F. Hoffmann-La Roche AG; GE Healthcare Life Science; Promega Corporation; PerkinElmer Inc.; Merck Millipore; Thermo Fisher Scientific Inc.; Kirkegaard & Perry Laboratories (KPL); Eurogentec S.A.; New England Biolabs; and LI-COR Inc.
Key players are involved in acquisition of smaller players and are expanding their product portfolio, resulting in market consolidation.

Epigenetics Market Size Worth $22.05 Billion By 2025

The global epigenetics market size is expected to reach USD 22.05 billion by 2025, according to a new study by Grand View Research, Inc., progressing at a CAGR of 19.7% during the forecast period. The growing prevalence of cancer and other diseases worldwide with an epigenetic modification base is expected to drive the market during the forecast period.

Diagnostic companies are coming up with new products such as antibodies specific for the detection of modifications and new upgraded kits for easy and efficient detection of biomarkers. This is estimated to attract pharmaceutical companies to collaborate for the development of therapeutic drugs, which will work in favor of the market.

The presence of pipeline drugs and their expected commercialization is anticipated to boost the growth of the market. For instance, Ramucirumab (Cyramza) by Eli Lilly and Company was approved by the FDA for use in combination with Folfiri for the treatment of patients with metastatic colorectal cancer.

Technology advancements in the epigenetics industry are majorly focusing on the detection of methylation markers related to cancer development. For instance, Epi proLung BL Reflex Assay by Epigenomics helps in the diagnosis of lung cancer by determining methylation of SHOX2 biomarker gene.

Click the link below:
https://www.grandviewresearch.com/industry-analysis/epigenetics-market

Further key findings from the study suggest:

On the basis of product, reagents held the largest share in the market in 2017. They are projected to amount to approximately USD 7.06 billion by 2025 owing to increasing R&D activities in the field of epigenetics
The kits segment is expected to post a CAGR of over 20.0% due to the need for rapid and accurate detection techniques
DNA methylation, on the basis of technology, held the leading revenue share in the market in 2017, accounting for just over 47.0%. The rapid adoption of advanced techniques such as methylation-sensitive PCR (MSP) to improve diagnostics efficiency is poised to bolster the growth of the segment
North America commanded the leading position in the global arena with a share of 40.0% in 2017. The growth of the regional market can be attributed to the increasing prevalence of cancer and growing collaborations between large pharmaceutical firms for the development of improved therapeutics
Asia Pacific is estimated to register a noteworthy CAGR of 22.1% during the forecast period owing to the presence of a large target population coupled with high unmet clinical needs
Some of the major players of epigenetics market are Illumina; Abcam; Diagenode; Thermo Fisher Scientific; Merck; Zymo research; Qiagen; CellCentric Ltd; Chroma Therapeutics Ltd; Eisai Co. Ltd; Novartis International AG; Oncolys Biopharma Inc.; Syndax Pharmaceuticals, Inc.; Valirx Plc; and Sigma-Aldrich Corporation
Extensive R&D initiatives for the development of novel drugs and the presence of strong product pipeline are expected to further boost market growth over the forecast period.